Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

BACKGROUND: Convenient administration of coronavirus disease 2019 (COVID-19) treatment in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action monoclonal antibody formulated for intravenous (IV) or intramuscular (IM) administration for early treatment of mild/moderate COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Adrienne E, Sarkis, Elias, Acloque, Jude, Free, Almena, Gonzalez-Rojas, Yaneicy, Hussain, Rubaba, Juarez, Erick, Moya, Jaynier, Parikh, Naval, Inman, David, Cebrik, Deborah, Nader, Ahmed, Noormohamed, Nadia, Wang, Qianwen, Skingsley, Andrew, Austin, Daren, Peppercorn, Amanda, Agostini, Maria L, Parra, Sergio, Chow, Sophia, Mogalian, Erik, Pang, Phillip S, Hong, David K, Sager, Jennifer E, Yeh, Wendy W, Alexander, Elizabeth L, Gaffney, Leah A, Kohli, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414803/
https://www.ncbi.nlm.nih.gov/pubmed/37577112
http://dx.doi.org/10.1093/ofid/ofad354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414803/
https://www.ncbi.nlm.nih.gov/pubmed/37577112
http://dx.doi.org/10.1093/ofid/ofad354

Ejemplares similares